iPSC-Derived CAR-T Cells for Consistent Manufacturing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current adoptive cell therapies using patient- and donor-sourced cells face challenges in achieving consistent manufacturing, improving efficacy and persistence of lymphocytes, and addressing issues like cell exhaustion, tumor escape, and off-target toxicity, particularly in delivering effective cancer immunotherapies.
Innovation Solution
The development of genome-engineered induced pluripotent stem cells (iPSCs) that are differentiated into non-pluripotent cells with specific genetic modifications, enabling targeted integration of exogenous polynucleotides for enhanced therapeutic properties such as improved persistence, expansion, and tumor penetration, using methods like CRISPR-mediated editing and chimeric antigen receptors (CARs) to promote desired effector cell functions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If patient- and donor-sourced cells are used for adoptive cell therapy, then personalized treatment can be provided, but manufacturing consistency and scalability are compromised
Solution Approach 1:
The patent uses iPSCs as a renewable source to generate multiple copies of patient-specific immune cells. By reprogramming patient cells into iPSCs and then differentiating them into CAR-T cells, the system creates a scalable manufacturing process that maintains patient specificity while enabling consistent production of large cell numbers for multiple treatments
Solution Approach 2:
The patent performs genetic engineering and CAR integration during the iPSC reprogramming and differentiation stage, before the actual therapy is administered. This preliminary engineering of the iPSC line ensures that all subsequent differentiated cells inherit the desired modifications, improving manufacturing consistency and reducing variability in the final therapeutic product
2Productivity
If primary lymphocytes are engineered directly, then rapid therapy production is possible, but cell persistence and expansion are compromised due to poor engineering reproducibility
Solution Approach 1:
The patent performs the complex genetic engineering operations during the iPSC reprogramming phase, before differentiation into functional lymphocytes. This preliminary action ensures that the engineering is completed when the cell population is still small and manageable, allowing for quality control and optimization, while the resulting iPSC line can then be expanded and differentiated repeatedly to produce consistent, persistent therapeutic cells
Solution Approach 2:
The engineered iPSCs possess self-renewal capacity, allowing them to generate large numbers of differentiated effector cells autonomously. This self-service capability eliminates the need for repeated engineering of primary cells and ensures consistent propagation of the desired genetic modifications through multiple cell generations, improving both reliability and persistence
3Adaptability or versatility
If heterogeneous primary cell sources are used, then diverse immune cell types can be obtained, but uniformity and reproducibility of therapeutic effect are compromised
Solution Approach 1:
The patent starts with a homogeneous iPSC population that can be genetically engineered with uniform precision. When these engineered iPSCs are differentiated, they produce clonal populations of effector cells that are highly uniform in their genetic composition and functional properties. This homogeneous starting point and controlled differentiation process ensures reproducible therapeutic effects while maintaining the ability to generate diverse cell types from the same iPSC line
Data Source
AI summary
Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from the differentiation of genomically engineered iPSCs. The derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.